



Ref: OPL/Share/2018/45
April 28, 2018

Managing Director
Dhaka Stock Exchange Ltd
9/F Motijheel C/A
Dhaka-1000.

Subject : Price Sensitive Information.

Dear Sir,

As per rule no. 33 of the DSE Listing Regulations, 2015, the Board of Directors of Orion Pharma Limited has adopted its un-audited 3rd quarterly financial statements in its Board Meeting held Today on April 28, 2018 at 5:30 pm in the registered office at Orion House, 153-154, Tejgaon I/A, Dhaka-1208. The following decisions were taken in the meeting :

		March 31, 2018		June 30, 2017	
Consolidated NAV per Share - Q3 (Including Revaluation Surplus)	:	BDT. 72.07		BDT. 70.95	
Consolidated NAV per Share - Q3 (Excluding Revaluation Surplus)	:	BDT. 63.71		BDT. 62.48	
		July 01, 2017 to March 31, 2018	July 01, 2016 to March 31, 2017	Jan 01, 2018 to March 31, 2018	Jan 01, 2017 to March 31, 2017
Consolidated Earnings Per Share (EPS)- Q3	:	BDT. 2.76	BDT. 3.02	BDT. 0.69	BDT. 0.56
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT. 8.57	BDT. 8.54	-----	-----

Please acknowledge the receipt.

Thanking you,

Sincerely yours'

Md. Ferdous Jaman
Company Secretary